Digital Library
Close Browse articles from a journal
 
Search for with title:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             90 results found
no title author magazine year volume issue page(s) type
1 Accurate Determination of Prostate Size Via Digital Rectal Examination and Transrectal Ultrasound Roehrborn, Claus G
 1998
 1-20 4S1 p. 19-22
4 p.
 article
2 African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials Powell, Isaac J
 2001
 1-20 4S1 p. 178-181
4 p.
 article
3 Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer Kelloff, Gary J
 2001
 1-20 4S1 p. 46-51
6 p.
 article
4 Analysis and presentation Friberg, Sten
 1997
 1-20 4S1 p. 54-65
12 p.
 article
5 Androgen antagonists: Potential role in prostate cancer prevention Trump, Donald L
 2001
 1-20 4S1 p. 64-67
4 p.
 article
6 Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials Ali, Iqbal Unnisa
 2001
 1-20 4S1 p. 143-147
5 p.
 article
7 Antioxidant dietary supplements: Rationale and current status as chemopreventive agents for prostate cancer Fleshner, Neil Eric
 2001
 1-20 4S1 p. 90-94
5 p.
 article
8 Apoptosis as a biomarker in chemoprevention trials Riss, Terry L
 2001
 1-20 4S1 p. 141-142
2 p.
 article
9 A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: Rationale, recruitment, and design issues Costello, Anthony J
 2001
 1-20 4S1 p. 182-184
3 p.
 article
10 Army and Air Force Leadership in The Prostate Cancer Prevention Trial 1 1 The opinions expressed herein are those of the authors and do not necessarily reflect those of the Departments of the Army or Defense. Allerton, Jeffrey
 1998
 1-20 4S1 p. 64-66
3 p.
 article
11 Assessment of endpoints for clinical trials for localized prostate cancer Schellhammer, Paul
 1997
 1-20 4S1 p. 27-38
12 p.
 article
12 Assessment of hormone refractory prostate cancer Newling, Don
 1997
 1-20 4S1 p. 46-53
8 p.
 article
13 Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer Weiss, Heidi L
 2001
 1-20 4S1 p. 220-223
4 p.
 article
14 Biologic Variability of Prostate-Specific Antigen and its Usefulness as a Marker for Prostate Cancer: Effects of Finasteride 1 1 Financial support for these studies was provided by Merck & Co., Inc., Rahway, New Jersey 2 2 This article was originally published in Urology, July 1997. Oesterling, Joseph E.
 1998
 1-20 4S1 p. 58-63
6 p.
 article
15 Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia Alberts, Steven R.
 2001
 1-20 4S1 p. 188-190
3 p.
 article
16 Chemoprevention trials in men with prostate-specific antigen failure or at high risk for recurrence after radical prostatectomy: Application to efficacy assessment of soy protein Bosland, Maarten C
 2001
 1-20 4S1 p. 202-204
3 p.
 article
17 Childbirth-induced trauma to the urethral continence mechanism: review and recommendations Baessler, Kaven
 2003
 1-20 4S1 p. 39-44
6 p.
 article
18 Complementary/alternative therapies for reducing hot flashes in prostate cancer patients: reevaluating the existing indirect data from studies of breast cancer and postmenopausal women Moyad, Mark A
 2002
 1-20 4S1 p. 20-33
14 p.
 article
19 Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research Moyad, Mark A
 2002
 1-20 4S1 p. 34-40
7 p.
 article
20 Comprehensive Patient Evaluation for Benign Prostatic Hyperplasia Jepsen, Jan V
 1998
 1-20 4S1 p. 13-18
6 p.
 article
21 Computer-assisted image analysis–derived intermediate endpoints Boone, Charles W.
 2001
 1-20 4S1 p. 129-131
3 p.
 article
22 Current Trends in Management of Men With Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia Holtgrewe, H.Logan
 1998
 1-20 4S1 p. 1-7
7 p.
 article
23 Design considerations for efficient prostate cancer chemoprevention trials Lee, J.Jack
 2001
 1-20 4S1 p. 205-212
8 p.
 article
24 Dietary fat reduction to reduce prostate cancer risk: controlled enthusiasm, learning a lesson from breast or other cancers, and the big picture Moyad, Mark A
 2002
 1-20 4S1 p. 51-62
12 p.
 article
25 Dietary trial in prostate cancer: Early experience and implications for clinical trial design Ornish, Dean M
 2001
 1-20 4S1 p. 200-201
2 p.
 article
26 Early clinical trials of chemopreventive and biologic agents: Designs, populations, and endpoints 1 1 The views expressed in this article do not necessarily represent those of or imply endorsement from the US Food and Drug Administration or the US government. Pursuant to 5 CFR §2635.807(b)(2), federal employees are required to include the preceding statement. Keegan, Patricia
 2001
 1-20 4S1 p. 216-219
4 p.
 article
27 Epidemiology and natural history of urinary incontinence in women Hunskaar, Steinar
 2003
 1-20 4S1 p. 16-23
8 p.
 article
28 Evaluation and follow-up of patients with n1-3 m0 or nxm1 prostate cancer in phase iii trials Hall, Reginald
 1997
 1-20 4S1 p. 39-45
7 p.
 article
29 Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations Lieberman, Ronald
 2001
 1-20 4S1 p. 4-27
24 p.
 article
30 Foreword Tindall, Donald J.
 2001
 1-20 4S1 p. vii-
1 p.
 article
31 Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia Sakr, Wael A
 2001
 1-20 4S1 p. 115-120
6 p.
 article
32 Home electrical stimulation for urinary incontinence: a study of the diffusion ofa new technology Indrekvam, Solfrid
 2003
 1-20 4S1 p. 24-30
7 p.
 article
33 How is quality of life in prostate cancer patients influenced by modern treatment? the wallenberg symposium Altwein, Jens
 1997
 1-20 4S1 p. 66-76
11 p.
 article
34 Imaging and prostate cancer chemoprevention: Littrup, Peter J
 2001
 1-20 4S1 p. 121-123
3 p.
 article
35 Introduction Moyad, Mark A.
 2002
 1-20 4S1 p. 1-3
3 p.
 article
36 Introduction Cardozo, Linda D.
 2003
 1-20 4S1 p. 1-2
2 p.
 article
37 Introduction Lieberman, Ronald
 2001
 1-20 4S1 p. 1-3
3 p.
 article
38 Introduction Andersson, Lennart
 1997
 1-20 4S1 p. 1-2
2 p.
 article
39 Introduction Marks, Leonard S.
1-20 4S1 p. 1
 article
40 Is obesity a risk factor for prostate cancer, and does it even matter? A hypothesis and different perspective Moyad, Mark A
 2002
 1-20 4S1 p. 41-50
10 p.
 article
41 Long-Term Implications of Medical Therapy on Benign Prostatic Hyperplasia End Points Nickel, J.Curtis
 1998
 1-20 4S1 p. 50-57
8 p.
 article
42 Magnetic resonance imaging and spectroscopic imaging: Improved patient selection and potential for metabolic intermediate endpoints in prostate cancer chemoprevention trials Kurhanewicz, John
 2001
 1-20 4S1 p. 124-128
5 p.
 article
43 Meta-Analysis of Randomized Clinical Trials of Finasteride Roehrborn, Claus G
 1998
 1-20 4S1 p. 46-49
4 p.
 article
44 Mind-body effect: insulinlike growth factor-1; clinical depression; and breast, prostate, and other cancer risk—an unmeasured and masked mediator of potential significance? Moyad, Mark A.
 2002
 1-20 4S1 p. 4-8
5 p.
 article
45 Minimally Invasive Alternative Therapeutic Options for Lower Urinary Tract Symptoms Kaplan MD, Steven A
 1998
 1-20 4S1 p. 32-37
6 p.
 article
46 Natural History and Epidemiology of Benign Prostatic Hyperplasia: Relationship Among Urologic Measures Girman, Cynthia J
 1998
 1-20 4S1 p. 8-12
5 p.
 article
47 New biologicals for prostate cancer prevention: Pantuck, Allan J
 2001
 1-20 4S1 p. 95-99
5 p.
 article
48 New concepts in the pathology of prostatic epithelial carcinogenesis De Marzo, Angelo M
 2001
 1-20 4S1 p. 103-114
12 p.
 article
49 New molecular approaches for identifying novel targets, mechanisms, and biomarkers for prostate cancer chemopreventive agents Williams, Elizabeth D
 2001
 1-20 4S1 p. 100-102
3 p.
 article
50 New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics Paweletz, Cloud P
 2001
 1-20 4S1 p. 160-163
4 p.
 article
51 Other novel agents: Rationale and current status as chemopreventive agents Tolcher, Anthony W
 2001
 1-20 4S1 p. 86-89
4 p.
 article
52 Overview of α-Blocker Therapy for Benign Prostatic Hyperplasia Narayan, Perinchery
 1998
 1-20 4S1 p. 38-45
8 p.
 article
53 Oxidative stress in chemoprevention trials DeWeese, Theodore L.
 2001
 1-20 4S1 p. 137-140
4 p.
 article
54 Percutaneous computed tomography–guided radiofrequency ablation of renal masses in high surgical risk patients: preliminary results Su, L.i-Ming
1-20 4S1 p. 26-33
 article
55 Pharmacologic treatment of stress urinary incontinence: expectations for outcome Schuessler, Bernhard
 2003
 1-20 4S1 p. 31-38
8 p.
 article
56 Phase II studies on prostate cancer Schröder, Fritz H.
 1997
 1-20 4S1 p. 3-14
12 p.
 article
57 Planning controlled clinical trials Denis, Louis
 1997
 1-20 4S1 p. 15-26
12 p.
 article
58 Potential target populations and clinical models for testing chemopreventive agents Klein, Eric A
 2001
 1-20 4S1 p. 171-173
3 p.
 article
59 Preprostatectomy: A clinical model to study stromal-epithelial interactions Lopaczynski, Wlodek
 2001
 1-20 4S1 p. 194-199
6 p.
 article
60 Proapoptotic anti-inflammatory drugs Myers, Charles
 2001
 1-20 4S1 p. 73-76
4 p.
 article
61 Prostate cancer chemoprevention: Strategies for designing efficient clinical trials Lieberman, Ronald
 2001
 1-20 4S1 p. 224-229
6 p.
 article
62 Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents Nelson, William G
 2001
 1-20 4S1 p. 56-63
8 p.
 article
63 Prostate cancer prevention strategies using antiproliferative or differentiating agents Walczak, Janet
 2001
 1-20 4S1 p. 81-85
5 p.
 article
64 Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents Partin, Alan W
 2001
 1-20 4S1 p. 132-136
5 p.
 article
65 Prostate-specific antigen–enhanced testing and risk stratification for chemoprevention trials 1 1 The opinions and assertions contained herein are the private views of the author and are not to be construed as reflecting the views of the US Army or the Department of Defense. Moul, Judd W
 2001
 1-20 4S1 p. 174-177
4 p.
 article
66 Quality of Life endpoints in prostate chemoprevention trials Sloan, Jeff A
 2001
 1-20 4S1 p. 235-240
6 p.
 article
67 Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia Clark, Larry C
 2001
 1-20 4S1 p. 185-187
3 p.
 article
68 Recent Developments in the Surgical Management of Benign Prostatic Hyperplasia Jepsen, Jan V
 1998
 1-20 4S1 p. 23-31
9 p.
 article
69 Robotic radical prostatectomy and the vattikuti urology institute technique: an interim analysis of results and technical points Menon, Mani
1-20 4S1 p. 15-20
 article
70 Selective estrogen receptor modulators for the chemoprevention of prostate cancer Steiner, Mitchell S
 2001
 1-20 4S1 p. 68-72
5 p.
 article
71 Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? Moyad, Mark A
 2002
 1-20 4S1 p. 9-19
11 p.
 article
72 Sequence databases and microarrays as tools for identifying prostate cancer biomarkers Grouse, Lynette H
 2001
 1-20 4S1 p. 154-159
6 p.
 article
73 Serotonergic modulation of bladder afferent pathways Burgard, Edward C
 2003
 1-20 4S1 p. 10-15
6 p.
 article
74 Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence Thor, Karl B
 2003
 1-20 4S1 p. 3-9
7 p.
 article
75 Similarities of prostate and breast cancer: Evolution, diet, and estrogens Coffey, Donald S
 2001
 1-20 4S1 p. 31-38
8 p.
 article
76 Standardization, analytical validation, and quality control of intermediate endpoint biomarkers Veltri, Robert W
 2001
 1-20 4S1 p. 164-170
7 p.
 article
77 State of research for prostate cancer: Excerpt∗ from the report of the Prostate Cancer Progress Review Group∗ ∗ For the full report, see: http://osp.nci.nih.gov/prgreports/pprgreport/toc.htm Tindall, Donald J.
 2001
 1-20 4S1 p. 28-30
3 p.
 article
78 Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial Hellstrom, Wayne J.G.
1-20 4S1 p. 8-14
 article
79 Sustaining the effort for cancer prevention Aldigé, Carolyn
 2001
 1-20 4S1 p. 52-55
4 p.
 article
80 Telomerase activity modulation in the prevention of prostate cancer Kim, Nam W.
 2001
 1-20 4S1 p. 148-153
6 p.
 article
81 The molecular pathogenesis of prostate cancer: Implications for prostate cancer prevention Nelson, William G
 2001
 1-20 4S1 p. 39-45
7 p.
 article
82 The Prostate Cancer Prevention Trial: Current status and lessons learned Thompson Jr, Ian M
 2001
 1-20 4S1 p. 230-234
5 p.
 article
83 The role of dihydrotestosterone in benign prostatic hyperplasia Carson III, Culley
1-20 4S1 p. 2-7
 article
84 The role of estrogens in female lower urinary tract dysfunction Robinson, Dudley
 2003
 1-20 4S1 p. 45-51
7 p.
 article
85 The role of prostate needle biopsy in evaluation of chemopreventive agents Marks, Leonard S
 2001
 1-20 4S1 p. 191-193
3 p.
 article
86 Trends toward less invasive treatment of female stress urinary incontinence Balmforth, James
 2003
 1-20 4S1 p. 52-60
9 p.
 article
87 Trial endpoints for drug approval in oncology: Chemoprevention 1 1 This article is not an official FDA guidance or policy statement. No official support or endorsement by the Food and Drug Administration is intended or should be inferred. Beitz, Julie
 2001
 1-20 4S1 p. 213-215
3 p.
 article
88 Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer Bergan, Raymond C
 2001
 1-20 4S1 p. 77-80
4 p.
 article
89 Urethrolysis with martius labial fat pad graft for iatrogenic bladder outlet obstruction Carey, Jeffrey M.
1-20 4S1 p. 21-25
 article
90 Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials Trock, Bruce J
 2001
 1-20 4S1 p. 241-247
7 p.
 article
                             90 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands